
Opinion|Videos|September 17, 2024
Prophylactic Strategies and Advice for Managing AEs in Bispecific Therapies
Author(s)Larysa Sanchez, MD, Samantha Shenoy, MSN, NP
Experts discuss prophylactic measures for managing potential adverse events associated with talquetamab and other bispecifics, while all faculty will offer advice for health care providers involved in the care of patients receiving talquetamab.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are some prophylactic measures taken to manage potential adverse events associated with talquetamab and other bispecifics?
- What advice do you have for other health care providers who are involved in or about to be involved in the care of patients on talquetamab?
Advertisement
Related to this article

Following WCLC 2026, Katherine Kuhns details how perioperative immunotherapy, AI patient tools, and wearables are transforming thoracic surgical nursing care.

Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.

Five-week hypofractionated radiation after prostatectomy showed similar 5-year cancer control and quality of life but more grade 3 urinary toxicity.

Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.

Dr. Wendy Harpham reflects on her journey as a physician and patient, emphasizing precise clinical communication in oncology care.

FDA approves pirtobrutinib for untreated CLL/SLL without 17p deletion based on BRUIN CLL-313 data. Read key nursing safety takeaways.

Most oral blood cancer drug prescriptions were first rejected by insurers, and fill rates fell sharply when out-of-pocket costs topped $175.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
IMS 2026: Beth Faiman Details First Consensus Definition of Myeloma Cure
2
Shorter Postprostatectomy Radiation Matches Standard Course
3
Community Case Forum Explores Advancements and Care Collaboration in CLL
4
WCLC 2026: Katherine Kuhns Details AI, Wearables & Perioperative Care Roles
5

